2023-08-09 07:44:50
The Mainz-based vaccine manufacturer Biontech is expected to launch its adapted Covid-19 vaccine in September. The company announced this when it presented its business figures for the second quarter on Monday in Mainz. Subject to approval, the delivery of the vaccine adapted to the Corona variant XBB.1.5, a sub-variant of Omicron, should then begin.
As with US partner Pfizer, the significantly lower business with Covid-19 vaccines is also having a strong impact on the Mainz-based company’s balance sheet. Biontech’s sales of corona vaccines fell to 1.4 billion euros in the first half of the year after 9.57 billion in the same period of the previous year. The profit collapsed from 5.37 billion euros to 311.8 million euros.
For the second quarter, which ended at the end of June, the bottom line was even a loss of 190.4 million euros, in the same quarter of the previous year Biontech had still made a profit of 1.67 billion euros. Quarterly revenues were EUR 167.7 million after EUR 3.2 billion in the same period of the previous year.
Biontech stuck to its forecast for the year as a whole and continues to expect sales of around 5 billion euros from Covid-19 vaccines. The company noted that it received several payments after the end of the second quarter, including an approximately $1.06 billion compensation payment from partner Pfizer for Biontech’s share of gross profit for the first quarter of 2023.
#Sixt #achieves #record #results #RTL #lowers #forecast #year